CDC Advisory Panel Shifts Hepatitis B Vaccination Guidance: What Parents Need to Know

In a significant change to longstanding policy, an advisory committee to the Centers for Disease Control and Prevention (CDC) has narrowed its recommendations for hepatitis B vaccination of newborns. The decision, made on December 5, 2025, moves the United States toward a model where vaccination decisions for infants are made on a case-by-case basis, depending on the mother’s hepatitis B status . This shift follows decades of universal vaccination at birth, a practice credited with dramatically reducing hepatitis B infections.

A History of Success: The Impact of Universal Vaccination

Since 1991, the CDC recommended screening pregnant women for hepatitis B virus (HBV) infection and vaccinating all medically stable infants against hepatitis B within 24 hours of birth . This strategy aimed to prevent both perinatal (during birth) and postnatal infection and ultimately eliminate HBV transmission nationwide. The results were striking: acute hepatitis B infections among children and teenagers decreased by 99% between 1990 and 2019 .

The New Recommendations: A Shift to Targeted Vaccination

The Advisory Committee on Immunization Practices (ACIP) now recommends that only infants born to mothers with known hepatitis B infection, or mothers whose status is unknown, receive the hepatitis B vaccine at birth . For all other newborns, the decision to vaccinate is left to parents and their healthcare providers. The new guidance also suggests testing infants for antibodies between vaccine doses, using the results to determine the need for further vaccination.

Understanding Hepatitis B: Transmission and Risks

Hepatitis B is a highly contagious virus spread through contact with infected body fluids – blood, semen, and vaginal secretions . Transmission can occur through sexual contact, shared needles for drug use, and from mother to child during birth. The virus can also survive on surfaces for up to seven days, posing a risk of transmission through shared personal items like toothbrushes or razors, or even through bites and playground accidents.

Although many adults clear the virus on their own, babies and young children are at significantly higher risk of developing chronic hepatitis B infection. Infants infected at birth have a 90% chance of developing a chronic infection, while those infected between ages one and five have a 30% chance . A quarter of those who develop chronic infection may eventually die from liver failure, liver cancer, or other complications.

The Safety and Effectiveness of the Hepatitis B Vaccine

The hepatitis B vaccine has a strong safety record, with over a billion doses administered worldwide since 1982 . Common side effects are typically mild, including headache, fever, or soreness at the injection site. The vaccine is highly effective in preventing infection and its serious consequences.

What This Means for Parents

The change in recommendations means parents will need to have a more active role in deciding whether their newborn receives the hepatitis B vaccine. It’s crucial to discuss the risks and benefits with your pediatrician, considering your individual circumstances and the prevalence of hepatitis B in your community. The CDC continues to recommend vaccination for all infants, but the timing and approach are now more flexible.

Hepatitis B Vaccine Administration

Hepatitis B vaccines are available as a single-antigen formulation and in combination with other vaccines. All hepatitis B vaccines contain yeast protein and aluminum adjuvant. For pregnant women who are at risk for HBV infection and have not been vaccinated previously, vaccination is recommended . The two single-antigen vaccines, Engerix-B and Recombivax-HB, can be used starting at birth .